[Amended] Material event report (decision to sell own convertible bonds)

What happened

Material Event Report (Decision to Sell Own Convertible Bonds) 6.0 GeneOne Life Science Co., Ltd. Amendment Report (Correction) July 29, 2026 1. Disclosure document being amended: Material event report (decision to sell own convertible bonds) 2. Original filing date of the disclosure document being amended: 2026.04.20 3. Amendment details

Item: 6. Pre-maturity acquisition details of the bonds to be sold - face (electronically registered) value of bonds to be sold (KRW); before amendment: 3,000,000,000; after amendment: 2,000,000,000 Item: 6. - acquisition amount (KRW); before amendment: 3,000,000,000; after amendment: 2,000,000,000 Item: 9. Sale proceeds receipt date; reason for amendment: postponement of the sale proceeds receipt date; before amendment: 2026.07.29; after amendment: 2026.10.29 Item: 11. Matters related to conversion - conversion price as of the report date (KRW/share); reason for amendment: conversion price adjustment due to a capital reduction without consideration (5:1 share consolidation); before amendment: 2,192; after amendment: 10,960 Item: 11. - number of shares to be issued upon conversion; before amendment: 684,306; after amendment: 136,861 Item: 13. Other matters material to investment decisions; reason for amendment: postponement of the sale proceeds receipt date; (Note 2) (Note 2)

[Before amendment, Note 1] 13. Other matters material to investment decisions - This decision to resell the convertible bonds concerns the resale of KRW 1,000,000,000 out of the KRW 2,000,000,000 face value of the "Series 6 unregistered unsecured private-placement convertible bonds" issued by the company on November 4, 2025 and acquired before maturity on December 5, 2025, together with KRW 500,000,000 out of the KRW 1,000,000,000 face value of the "Series 6 unregistered unsecured private-placement convertible bonds" acquired before maturity on March 5, 2026. - Related disclosures: 2025.12.05 Material event report (decision to acquire own convertible bonds before maturity); 2026.03.06 Material event report (decision to acquire own convertible bonds before maturity); 2026.04.20 Material event report (decision to sell own convertible bonds); 2026.04.28 Material event report (1st amendment, decision to sell own convertible bonds) - The sale proceeds from this resale of the convertible bonds are expected to be received on July 29, 2026.

[Matters Related to the Buyer] Sunkwang System Co., Ltd.: relationship to the company or largest shareholder: none; selection process: selected considering the investor's intent, payment capacity, timing, etc., to achieve the company's management objectives and promptly raise needed funds; transactions within 6 months before/after the sale decision: plans to purchase these convertible bonds on July 29, 2026; face value of bonds purchased (KRW): 1,500,000,000; note -

[After amendment, Note 2] 13. Other matters material to investment decisions - This decision to resell the convertible bonds concerns the resale of KRW 1,000,000,000 out of the KRW 2,000,000,000 face value of the "Series 6 unregistered unsecured private-placement convertible bonds" issued by the company on November 4, 2025 and acquired before maturity on December 5, 2025, together with KRW 500,000,000 out of the KRW 1,000,000,000 face value of the "Series 6 unregistered unsecured private-placement convertible bonds" acquired before maturity on March 5, 2026. - Related disclosures: 2025.12.05 Material event report (decision to acquire own convertible bonds before maturity); 2026.03.06 Material event report (decision to acquire own convertible bonds before maturity); 2026.04.20 Material event report (decision to sell own convertible bonds); 2026.04.28 Material event report (1st amendment, decision to sell own convertible bonds); 2026.05.29 Material event report (2nd amendment, decision to sell own convertible bonds) - The sale proceeds from this resale of the convertible bonds are expected to be received on October 29, 2026. - In the 2026.04.28 [2nd amendment] disclosure of the decision to sell own convertible bonds, the pre-maturity acquisition details of the bonds to be sold were mistakenly stated as KRW 3,000,000,000; as acquisitions and sales actually took place as set out below, this is being corrected to KRW 2,000,000,000. 6. Pre-maturity acquisition of the bonds to be sold (including sale details) * 2025.10.29 Decision to issue Series 6 convertible bonds (KRW 5,000,000,000) * 2025.12.05 Pre-maturity acquisition of convertible bonds (Series 6 CB, KRW 2,000,000,000) * 2025.12.31 Sale of own convertible bonds (Series 6 CB, KRW 1,000,000,000) * 2026.03.05 Pre-maturity acquisition of convertible bonds (KRW 1,000,000,000) * As of 2026.07.29, KRW 2,000,000,000 (Series 6 CB) of own convertible bonds remains outstanding. * Once the own convertible bonds (Series 6 CB, KRW 1,500,000,000) are sold on October 29, 2026 under this 3rd amendment, KRW 500,000,000 of own convertible bonds will remain outstanding.

[Matters Related to the Buyer] Sunkwang System Co., Ltd.: relationship to the company or largest shareholder: none; selection process: selected considering the investor's intent, payment capacity, timing, etc., to achieve the company's management objectives and promptly raise needed funds; transactions within 6 months before/after the sale decision: plans to purchase these convertible bonds on October 29, 2026; face value of bonds purchased (KRW): 1,500,000,000; note -

Material Event Report / Exchange Reporting Obligation To the Financial Services Commission / Korea Exchange April 20, 2026 Company name: GeneOne Life Science Co., Ltd. CEO: Kim Kyung-jin, Han Woo-geun Head office address: 5 Digital-ro 26-gil, Guro-gu, Seoul (Phone) 02-6949-4056 (Website) https://www.genels.com Preparer: (Title) Managing Director (Name) Jeon Gyeong-ha (Phone) 02-6949-4056

Decision to Sell Own Convertible Bonds

1. Type of bond: Series 6, unregistered unsecured private-placement convertible bonds 2. Bond issuance date: November 4, 2025 3. Bond issuance method: Private placement 4. Bond maturity date: November 4, 2028 5. Total face (electronically registered) value of the bonds (KRW): 5,000,000,000 6. Details of early acquisition of the bonds to be sold: face (electronically registered) value of bonds to be sold (KRW): 2,000,000,000; acquisition amount (KRW): 2,000,000,000; reason for acquisition: early acquisition before maturity under agreement with the bondholder 7. Sale decision date: April 20, 2026 8. Sale amount: KRW 1,500,000,000; basis for determination: determined through negotiation with the buyer, considering the current share price situation and conversion requests on the convertible bonds, etc. 9. Sale proceeds receipt (expected) date: October 29, 2026 10. Purpose of sale: Working capital 11. Matters related to conversion: conversion ratio 100%; conversion price as of the report date (KRW/share): 10,960; type of shares to be issued upon conversion: GeneOne Life Science Co., Ltd. registered common shares; number of shares: 136,861; ratio to total shares outstanding: 0.75%; conversion request period: start date November 4, 2026; end date October 4, 2028 12. Whether subject to Fair Trade Commission reporting: Not applicable 13. Other matters material to investment decisions - This decision to resell the convertible bonds concerns the resale of KRW 1,000,000,000 out of the KRW 2,000,000,000 face value of the "Series 6 unregistered unsecured private-placement convertible bonds" issued by the company on November 4, 2025 and acquired before maturity on December 5, 2025, together with KRW 500,000,000 out of the KRW 1,000,000,000 face value of the "Series 6 unregistered unsecured private-placement convertible bonds" acquired before maturity on March 5, 2026. - Related disclosures: 2025.12.05 Material event report (decision to acquire own convertible bonds before maturity); 2026.03.06 Material event report (decision to acquire own convertible bonds before maturity); 2026.04.20 Material event report (decision to sell own convertible bonds); 2026.04.28 Material event report (1st amendment, decision to sell own convertible bonds); 2026.05.29 Material event report (2nd amendment, decision to sell own convertible bonds) - The sale proceeds from this resale of the convertible bonds are expected to be received on October 29, 2026. - In the 2026.04.28 [2nd amendment] disclosure of the decision to sell own convertible bonds, the pre-maturity acquisition details of the bonds to be sold were mistakenly stated as KRW 3,000,000,000; as acquisitions and sales actually took place as set out below, this is being corrected to KRW 2,000,000,000. 6. Pre-maturity acquisition of the bonds to be sold (including sale details) * 2025.10.29 Decision to issue Series 6 convertible bonds (KRW 5,000,000,000) * 2025.12.05 Pre-maturity acquisition of convertible bonds (Series 6 CB, KRW 2,000,000,000) * 2025.12.31 Sale of own convertible bonds (Series 6 CB, KRW 1,000,000,000) * 2026.03.05 Pre-maturity acquisition of convertible bonds (KRW 1,000,000,000) * As of 2026.07.29, KRW 2,000,000,000 (Series 6 CB) of own convertible bonds remains outstanding. * Once the own convertible bonds (Series 6 CB, KRW 1,500,000,000) are sold on October 29, 2026 under this 3rd amendment, KRW 500,000,000 of own convertible bonds will remain outstanding.

[Matters Related to the Buyer] Sunkwang System Co., Ltd.: relationship to the company or largest shareholder: none; selection process: selected considering the investor's intent, payment capacity, timing, etc., to achieve the company's management objectives and promptly raise needed funds; transactions within 6 months before/after the sale decision: plans to purchase these convertible bonds on October 29, 2026; face value of bonds purchased (KRW): 1,500,000,000; note -

[Where the Buyer Includes a Corporation or Organization] (1) Basic information on the corporation or organization Sunkwang System Co., Ltd.: number of investors 4; representative (managing partner): Ryu Mi-won, 76.94%; operator (managing partner): -; largest shareholder (largest investor): Ryu Mi-won, 76.94% (2) Key financial information for the most recent fiscal year (Unit: KRW million) Fiscal year: December 2025; total assets: 5,041; revenue: 3,594; total liabilities: 3,208; net income: 204; total equity: 1,834; external auditor: -; paid-in capital: 1,112; audit opinion: -